Bradley L. Campbell Will Lead Travere Therapeutics

The former Amicus Therapeutics executive will take over the role of president and CEO on December 1, 2026.

Updated on Sept. 21, 2026 in People

Isometric editorial illustration of a clean, geometric laboratory building facade in muted teal and ochre, representing corporate leadership transition. — Travere Therapeutics has appointed Bradley L. Campbell as its next president and CEO, effective December 1, 2026, succeeding Eric Dube. AI Illustration. Upload story photo >

Live Poll

Does a planned CEO transition change how much you trust a public company's future performance?

Travere Therapeutics has announced that Bradley L. Campbell will become the company's president and chief executive officer on December 1, 2026. He succeeds Eric Dube, who led the San Diego-based firm since January 2019.

Why it matters

The leadership change follows Eric Dube's decision to step down to prioritize his family and health. To ensure a smooth transition, Dube will remain with the organization as an executive advisor until February 15, 2027.

The incoming CEO brings over 25 years of biopharmaceutical experience to his new role. The outgoing executive led the company for a total of 8 years starting in 2019.

The players

Bradley L. Campbell

He is the incoming president and chief executive officer of Travere Therapeutics who previously served as the president and CEO of Amicus Therapeutics.

Eric Dube

He is the outgoing president and chief executive officer of Travere Therapeutics who has led the firm since 2019 and will transition to an executive advisor role.

Travere Therapeutics

This San Diego-based biopharmaceutical company focuses on developing therapies for rare diseases.

The details

The Board of Directors selected Campbell following a comprehensive search process. The transition plan includes Dr. Dube working closely with his successor in an advisory capacity throughout the winter months.

Eric Dube became president and CEO in January 2019.
Bradley L. Campbell assumes his new role on December 1, 2026.
Eric Dube ends his service as executive advisor on February 15, 2027.

Market Landscape

This leadership transition aligns with the biopharmaceutical industry standard of executing multi-month succession plans to maintain stability. The appointment positions the San Diego firm to continue its research trajectory under new management.

The transition process is designed to ensure operational stability and uninterrupted service for patients and partners. Customers and stakeholders should expect consistent company leadership during the advisor period through early 2027.

The takeaway

Effective leadership transitions in the biotech sector often prioritize lengthy advisory periods to preserve institutional knowledge. Investors and stakeholders typically view these structured handoffs as a signal of organizational health.